EPG Wealth Management LLC Takes $1.01 Million Position in Astrazeneca Plc $AZN

EPG Wealth Management LLC acquired a new stake in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, Holdings Channel reports. The firm acquired 10,933 shares of the company’s stock, valued at approximately $1,005,000.

Several other large investors have also made changes to their positions in the business. HB Wealth Management LLC lifted its position in shares of Astrazeneca by 5.0% in the fourth quarter. HB Wealth Management LLC now owns 49,922 shares of the company’s stock valued at $4,589,000 after acquiring an additional 2,364 shares in the last quarter. Caprock Group LLC lifted its position in shares of Astrazeneca by 13.8% in the fourth quarter. Caprock Group LLC now owns 43,939 shares of the company’s stock valued at $4,039,000 after acquiring an additional 5,344 shares in the last quarter. Kingswood Wealth Advisors LLC lifted its position in shares of Astrazeneca by 180.8% in the fourth quarter. Kingswood Wealth Advisors LLC now owns 9,024 shares of the company’s stock valued at $830,000 after acquiring an additional 5,810 shares in the last quarter. Bedel Financial Consulting Inc. purchased a new stake in shares of Astrazeneca in the fourth quarter worth about $221,000. Finally, Salomon & Ludwin LLC lifted its position in shares of Astrazeneca by 56.3% in the fourth quarter. Salomon & Ludwin LLC now owns 1,197 shares of the company’s stock worth $109,000 after buying an additional 431 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Performance

Shares of AZN stock opened at $194.99 on Thursday. Astrazeneca Plc has a 1 year low of $132.32 and a 1 year high of $212.71. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. The company has a market cap of $302.42 billion, a price-to-earnings ratio of 33.59, a P/E/G ratio of 1.47 and a beta of 0.35.

Astrazeneca Dividend Announcement

The business also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a dividend of $1.595 per share. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio is 74.83%.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late?stage Ultomiris data met the primary endpoint in IgA nephropathy (IgAN), showing a statistically significant reduction in proteinuria — a clinical signal that supports potential accelerated approvals and expands the drug’s addressable rare?kidney market. AstraZeneca’s Ultomiris reduces urine protein in late-stage trial of rare kidney disease
• Positive Sentiment: Tozorakimab recorded a third consecutive Phase III win in COPD, prompting Citi to raise its conviction in the drug’s blockbuster potential and model a path toward roughly $5bn peak sales — a meaningful upside case for long?term revenue growth. AstraZeneca’s tozorakimab treble puts $5bn sales ceiling in sight, says Citi
• Neutral Sentiment: Analysts are reassessing valuation after mixed short?term momentum: the stock has delivered strong 1?year returns but recent price action is softer, leaving investors to balance impressive clinical progress with an already sizable market cap. Assessing AstraZeneca (LSE:AZN) Valuation As Strong 1?Year Returns Contrast With Softer Recent Momentum
• Negative Sentiment: Regulatory/payer risk: AZN’s CEO warned that Germany’s cost?containment plans risk limiting patient access to new drugs the company plans to launch — a reminder that pricing and reimbursement policies in major markets could blunt upside from recent clinical wins. Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Analyst Ratings Changes

A number of equities research analysts recently commented on AZN shares. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. Wall Street Zen downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Weiss Ratings started coverage on Astrazeneca in a research report on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Finally, Citigroup started coverage on Astrazeneca in a research report on Tuesday, January 27th. They issued a “buy” rating on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.67.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.